Clinical trial
A Repeated Dose Study of the Metabolism and Action Evaluation of OROS…
NCT00410878 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00410878 |
|---|---|
| Title | A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain |
| Official title | A Repeated-Dose Pharmacokinetic Evaluation of Dilaudid SR Tablets (Hydromorphone HCI) in Patients With Chronic Pain |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pain, Analgesics, Opioid |
| Intervention type | Drug |
| Interventions | OROS Hydromorphone HCI (slow release) |
| Enrollment | 22 |
| Completion | Aug 1, 1999 |
| First posted | Dec 13, 2006 |
| Last update posted | Feb 17, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: